This drug was developed by Alexion Pharmaceuticals, Inc.
It was approved by the US Food and Drug Administration in December 2018. In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|